EU panel backs AbbVie's Rinvoq for vitiligo treatment
AbbVie (NYSE: ABBV) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
